Literature DB >> 12051736

Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells.

Dae-Yeol Lee1, Ho Keun Yi, Pyoung Han Hwang, Youngman Oh.   

Abstract

Insulin-like growth factor (IGF)-I and -II are potent mitogens and their mitogenic effects are modulated by IGF binding proteins (IGFBPs). In this study, we evaluated whether the enhanced expression of IGFBP-3 may increase the sensitivity of human gastric cancer cells to the anticancer drugs. We further investigated the potential mechanism for the growth inhibitory effect of anticancer drug induced-IGFBP-3 expression. These IGFBP-3-expressing gastric cancer cells showed a lower proliferation rate than IGFBP-3-non-expressing cells. Treatment with anticancer drugs resulted in up-regulation of IGFBP-3 expression in IGFBP-3-expressing cells. Interestingly the anticancer drug-induced-growth inhibition was more evident in IGFBP-3-expressing cells causing the IGFBP-3 expressing cells but not the IGFBP-3 non-expressing cells to accumulate in the G1/G0 phase and induce apoptosis. The exogenous addition of IGFBP-3 inhibited the growth of IGFBP-3-non-expressing cells, causing them to undergo apoptosis. Our data suggest that IGFBP-3 may have an important role in the biology of gastric cancer cell growth and provides a potential marker for predicting the responsiveness to anticancer drugs. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051736     DOI: 10.1016/S0006-291X(02)00491-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-κB activity in gastric cancer cells.

Authors:  Min Sun Kim; Dae-Yeol Lee
Journal:  Mol Cell Biochem       Date:  2015-02-07       Impact factor: 3.396

Review 2.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

3.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

4.  Epstein-Barr virus-specific methylation of human genes in gastric cancer cells.

Authors:  Julie L Ryan; Richard J Jones; Shannon C Kenney; Ashley G Rivenbark; Weihua Tang; Elizabeth Rw Knight; William B Coleman; Margaret L Gulley
Journal:  Infect Agent Cancer       Date:  2010-12-31       Impact factor: 2.965

5.  Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells.

Authors:  Marati R Vijayababu; A Arunkumar; P Kanagaraj; J Arunakaran
Journal:  J Carcinog       Date:  2006-04-06

6.  Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer.

Authors:  Chen-Hui Liu; Hong-Guang Bao; Ya-Li Ge; Shu-Kui Wang; Yan Shen; Li Xu
Journal:  Oncol Lett       Date:  2013-03-29       Impact factor: 2.967

7.  IGFBP3, a transcriptional target of homeobox D10, is correlated with the prognosis of gastric cancer.

Authors:  Meng Xue; Yanfei Fang; Guoming Sun; Wei Zhuo; Jing Zhong; Cuijuan Qian; Lan Wang; Liangjing Wang; Jianmin Si; Shujie Chen
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

8.  PPARγ induces growth inhibition and apoptosis through upregulation of insulin-like growth factor-binding protein-3 in gastric cancer cells.

Authors:  S Y Kim; M S Kim; M K Lee; J S Kim; H K Yi; S Y Nam; D Y Lee; P H Hwang
Journal:  Braz J Med Biol Res       Date:  2015-01-13       Impact factor: 2.590

9.  Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.

Authors:  Jheri J Dupart; Jonathan C Trent; Ho-Young Lee; Kenneth R Hess; Andrew K Godwin; Takahiro Taguchi; Wei Zhang
Journal:  Mol Cancer       Date:  2009-11-10       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.